Headache News and Research

Latest Headache News and Research

Raltegravir drug combo works against highly resistant strain of HIV

A study involving an international team of scientists has discovered that a new drug when combined with other anti-HIV medications, is particularly effective against a highly resistant strain of the HIV virus.

24 Jul 2008

Patent for Aciphex ruled valid and enforceable

PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for Aciphex (rabeprazole sodium 20 mg tablets) is valid and enforceable.

21 Jul 2008

New clues to the biological basis of migraines

Fifteen percent to 20 percent of people worldwide suffer from migraines - excruciating headaches often presaged by dramatic sensations, or "auras." By studying a rare, inherited form of migraine, researchers at Vanderbilt University Medical Center have found clues to the biological basis of the painful, debilitating disorder.

1 Jul 2008

Hand-held magnetic pulse device relieves migraines

The therapy known as noninvasive transcranial magnetic stimulation, or TMS, sparks a magnetic pulse which, when held against a person's head, creates an electric current among the nerves cells of the brain.

30 Jun 2008

Novel electronic device "zaps" away migraine pain

A novel electronic device designed to "zap" away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at The Ohio State University Medical Center.

26 Jun 2008

Women, Latinos face higher brain aneurysm risk

A type of stroke that can strike at any age, and kills one-third of its victims, appears to be more common in women and Mexican-Americans than in non-Hispanic white men, according to a new study from the University of Michigan Stroke Program.

15 Jun 2008

Hope on the horizon for migraine sufferers

A generation of anti-migraine drugs with fewer side effects than existing treatments could be available to sufferers within three years.

11 Jun 2008

St. John's wort not effective for treating ADHD

Children and teens with attention-deficit/hyperactivity disorder (ADHD) who were treated with the herb St. John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo, according to a study in the June 11 issue of JAMA, the Journal of the American Medical Association.

11 Jun 2008

Cancer patients report less fatigue while taking narcolepsy drug

A large, phase III clinical study showed the drug modafinil (Provigil) alleviated severe cancer-related fatigue for many patients, paving the way for the first reliable treatment for this debilitating and common side effect.

5 Jun 2008

Nearly one in five teenagers admit eating problems, but anxiety is a bigger problem than appearance

Eighteen per cent of school children who took part in two health surveys carried out a year apart admitted they had eating problems, according to research published in the latest Journal of Advanced Nursing.

4 Jun 2008

New lifesaving options come to Rochester for stroke

While Superbowl Sunday started out like any other Sunday for Webster resident Christine Skolnick, by kick-off time, things clearly went from bad to worse for the 42-year-old mother of two. An apparent stomach virus and mild headache at midday had, by 6 p.m., become deadly, as Skolnick's face drooped on her right side, and she had difficulty moving her right legs and arms.

20 May 2008

FDA approves new formulation of genetically engineered version of Factor VIIa plasma protein

The U.S. Food and Drug Administration today approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood. The new formulation allows the product to be stored at room temperature (up to 81 degrees Fahrenheit) for up to two years.

9 May 2008

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating a variety of neurological conditions. Surprisingly, the drug may not be effective for chronic headaches, accrding to Allison Brashear, M.D., professor and chairman of the Department of Neurology at Wake Forest University Baptist Medical Center, who helped develop the guidelines.

9 May 2008

FDA approves Strattera for ADHD in children and adolescents

Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

8 May 2008

Nutrition for the growing athlete: The good, the bad and the ugly

For millions of American children and teens playing sports, good nutrition is critical for maximum health, performance and normal growth.

8 May 2008

Botulinum toxin is safe and effective for treating cervical dystonia

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating cervical dystonia, a condition of involuntary head tilt or neck movement, spasticity and other forms of muscle overactivity that interfere with movement in adults and children with an upper motor neuron syndrome, and excessive sweating of the armpits and hands.

5 May 2008

AstraZeneca submits sNDA for SYMBICORT in chronic obstructive pulmonary disease

AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

30 Apr 2008

Study explains why steroid therapy for sinusitis and asthma loses its punch over time

Scientists at Johns Hopkins have outlined a new path for potential therapies to combat inflammation associated with sinusitis and asthma based on a new understanding of the body's earliest immune response in the nose and sinus cavities.

29 Apr 2008

Cell-based therapy shows promise in patients with Parkinson's disease

Rush University Medical Center neurosurgeon Dr. Roy A. E. Bakay and colleagues from Emory University, Atlanta found the therapy Spheramine was well-tolerated and patients experienced improvement in Parkinsonian symptoms (tremor, rigidity, slowness of movements, and impaired balance and coordination.)

28 Apr 2008